Privacy Curtain Changing and Cleaning Policies

Curtains_wmicrobes_final_10.17.11We’re just back from the Association for Professionals in Infection Control (APIC) conference in Ft. Lauderdale, and we read with interest a poster called Hospital Privacy Curtains: Cleaning and Changing Policies – Are We Doing Enough? presented there. Spoiler alert: the answer is no.

The investigators surveyed 49 infection control professionals in six states about privacy curtain management in standard patient rooms and ambulatory care rooms. They found that:

  • 96% use privacy curtains in patient rooms
  • 55% had a written policy on the frequency of cleaning privacy curtains
  • 53% had a written policy on the frequency of changing privacy curtains
  • 37% clean privacy curtains in a standard hospital room ‘only when visibly soiled’
  • 13% clean privacy curtains in a standard hospital room ‘every month’
  • 13% clean privacy curtains in a standard hospital room ‘every 3 months’
  • 13% clean privacy curtains in a standard hospital room ‘once per year’
  • 39% responded ‘Other’ to the question of how frequently they clean privacy curtains
  • Curtains were most often changed or cleaned when a patient had been discharged from an isolation room for a multi-drug resistant organism
  • 82% of respondents felt that hospital curtains are a potential source of transmission of healthcare associated infections
  • 86% felt that management of hospital curtains could be improved

We’re not surprised at these results. They are yet one more confirmation that the issue of soft surface contamination is not being sufficiently addressed. We hope some APIC attendees and other infection control professionals will view the poster and make some of the improvements in how privacy curtains are handled. We look forward to better results in future surveys.

 

PurThreadTM Technologies Inc. is dedicated to developing proprietary antimicrobial textile technology. Our patent-pending, integration technology and fiber formulations incorporate an EPA-registered antimicrobial additive into every fiber and yarn to protect the fabric from degradation. Learn more about our antimicrobial textile technology.

PurThread also makes a range of freshness products for other markets such as the military, emergency first responders and performance athletic wear in which our next-generation technology and fiber formulations expand the high performance options available to protect fabrics from odor, mold and mildew causing bacteria.

Scientifically Driven

We were pleased to announce the publication of a recent clinical study (Novel Hospital Curtains with Antimicrobial Properties: A Randomized, Controlled Trial) of our privacy curtains by the University of Iowa Carver College of Medicine.We were pleased to announce the publication of a recent clinical study (Novel Hospital Curtains with Antimicrobial Properties: A Randomized, Controlled Trial1) of our privacy curtains by the University of Iowa Carver College of Medicine. The study used a controlled, randomized, double-blind methodology to measure the resistance to contamination of our curtains compared to standard curtains.

Why is a clinical study important to us? The PurThread team comes from a scientific background, and thus, believes in the validity of using scientific research—from both the clinic and the lab—to support claims. That’s why, from its earliest days, the company’s strategy has been to make sure any claims or information can be backed up by research data. We understand that hospital administrators need data that can drive or support their budget and purchasing decisions.

We were encouraged by the results of this latest study. Some might have used those results to claim that this “proved” our fiber’s effectiveness. As a scientifically-driven company, we’re much more conservative about the meaning of those results. (OK, to be honest, our marketing team had a moment, but it passed quickly as their scientific nature reined in their exuberance.) At PurThread, we are encouraged because a rigorous clinical study suggests that the antimicrobial materials we are developing can have a meaningful impact in a clinical setting. In other words, the study indicates that we’re moving in the right direction, that we’re making progress, and that our approach is valid.

Watch this space for more data-rich information as we continue to develop—and rigorously test—our products.

1 Marin Schweizer, PhD; Maggie Graham, MS;  Michael Ohl, MD, MSPH; Kris Heilmann, BS; Linda Boyken, BS; Daniel Diekema, MD  Infection Control and Hospital Epidemiology Vol. 33, No. 11 (November 2012), pp. 1081-1085 Published by the University of Chicago Press.